IFPA-WHO: Psoriasis pact

The International Federation of Psoriasis Associations (IFPA) and the WHO Foundation have signed a multi-year agreement to bolster WHO's efforts in enhancing global understanding, diagnosis, and care for psoriasis, affecting over 100 million people worldwide.

This partnership marks a key milestone, focusing on updating the 2016 Global Report on Psoriasis, strengthening evidence-based policies, and improving access, especially in low- and middle-income countries where diagnosis gaps persist.

Priorities include sharing policy guidance with WHO member states, developing AI-driven diagnostic tools for low-resource areas, and training healthcare professionals.

IFPA Executive Director Frida Dunger hailed it as a "pivotal moment" for the psoriasis community, enabling better lives through WHO's leadership, while WHO Foundation CEO Anil Soni noted psoriasis's links to noncommunicable diseases, mental health, and universal health coverage.

Relevance to the UK
As a PAPAA member organisation under IFPA, this collaboration advances UK advocacy for psoriasis and psoriatic arthritis by aligning with global standards on policy, digital tools, and training, potentially informing NHS improvements and patient support. We will enagage with the work as it progresses.

Source:
IFPA press release via PRNewswire